|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Path tracking control of autonomous agricultural mobile robots显示文摘In a tractor automatic navigation system, path planning plays a significant role in improving operation efficiency. This study aims to create a suboptimal reference course for headland turning of a robot tractor and design a path-tracking controller to guide the robot tractor along the reference course. A time-minimum suboptimal control method was used to generate the reference turning course based on the mechanical parameters of the test tractor. A path-tracking controller consisting of both feedforward and feedback component elements was also proposed. The feedforward component was directly determined by the desired steering angle of the current navigation point on the reference course, whereas the feedback component was derived from the designed optimal controller. Computer simulation and field tests were performed to validate the path-tracking performance. Field test results indicated that the robot tractor followed the reference courses precisely on flat meadow, with average and standard lateral devia- tions being 0.031 m and 0.086 m, respectively. However, the tracking error increased while operating on sloping meadow due to the employed vehicle kinematic model. | ZHU Zhong-xiang CHEN Jun YOSHIDA Toyofumi TORISU Ryo SONG Zheng-he MAO En-rong | 2007 | Journal of Zhejiang University-Science A(Applied Physics & Engineering)2007，8，10： | 14 |
| 2 | Measurement of prostaglandin metabolites is useful in diagnosis of small bowel ulcerations显示文摘BACKGROUND We recently reported on a hereditary enteropathy associated with a gene encoding a prostaglandin transporter and referred to as chronic enteropathy associated with SLCO2 A1 gene(CEAS). Crohn's disease(CD) is a major differential diagnosis of CEAS, because these diseases share some clinical features. Therefore, there is a need to develop a convenient screening test to distinguish CEAS from CD.AIM To examine whether prostaglandin E major urinary metabolites(PGE-MUM) can serve as a biomarker to distinguish CEAS from CD.METHODS This was a transactional study of 20 patients with CEAS and 98 patients with CD.CEAS was diagnosed by the confirmation of homozygous or compound heterozygous mutation of SLCO2 A1. We measured the concentration of PGEMUM in spot urine by radioimmunoassay, and the concentration was compared between the two groups of patients. We also determined the optimal cut-off value of PGE-MUM to distinguish CEAS from CD by receiver operating characteristic(ROC) curve analysis.RESULTS Twenty Japanese patients with CEAS and 98 patients with CD were enrolled.PGE-MUM concentration in patients with CEAS was significantly higher than that in patients with CD(median 102.7 vs 27.9 μg/g × Cre, P < 0.0001). One log unit increase in PGE-MUM contributed to 7.3 increase in the likelihood for the diagnosis of CEAS [95% confidence interval(CI) 3.2-16.7]. A logistic regression analysis revealed that the association was significant even after adjusting confounding factors(adjusted odds ratio 29.6, 95%CI 4.7-185.7). ROC curve analysis revealed the optimal PGE-MUM cut-off value for the distinction of CEAS from CD to be 48.9 μg/g × Cre with 95.0% sensitivity and 79.6% specificity.CONCLUSION PGE-MUM measurement is a convenient, non-invasive and useful test for the distinction of CEAS from CD. | Yuichi Matsuno Junji Umeno Motohiro Esaki Yoichiro Hirakawa Yuta Fuyuno Yasuharu Okamoto Atsushi Hirano Shigeyoshi Yasukawa Fumihito Hirai Toshiyuki Matsui Shuhei Hosomi Kenji Watanabe Naoki Hosoe Haruhiko Ogata Tadakazu Hisamatsu Shunichi Yanai Shuji Kochi Koichi Kurahara Tsuneyoshi Yao Takehiro Torisu Takanari Kitazono Takayuki Matsumoto | 2019 | World Journal of Gastroenterology2019，25，14： | 5 |
| 3 | Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis显示文摘AIM To evaluate the therapeutic effects of ursodeoxycholic acid(UDCA) on autoimmune hepatitis(AIH).METHODS A total 136 patients who were diagnosed with AIH were included in our study. All of the patients underwent a liver biopsy, and had at least a probable diagnosis on the basis of either the revised scoring system or the simplified scores. Initial treatment included UDCA monotherapy(Group U, n = 48) and prednisolone(PSL) monotherapy(Group P, n = 88). Group U was further classified into two subgroups according to the effect of UDCA: Patients who had achieved remission induction with UDCA monotherapy and showed no sign of relapse(Subgroup U1, n = 34) and patients who additionally received PSL during follow-up(Subgroup U2, n = 14). We compared the clinical and histological findings between each groups, and investigated factorscontributing to the response to UDCA monotherapy.RESULTS In Group U, 34 patients(71%) achieved and maintained remission over 49(range: 8-90) mo(Subgroup U1) and 14 patients(29%) additionally received PSL(Subgroup U2) during follow-up. Two patients in Subgroup U2 achieved remission induction once but additionally required PSL administration because of relapse(15 and 35 mo after the start of treatment). The remaining 12 patients in Subgroup U2 failed to achieve remission induction during follow-up, and PSL was added during 7(range: 2-18) mo. Compared with Subgroup U2, Subgroup U1 had significantly lower alanine aminotransferase(ALT) levels at onset(124 IU/L vs 262 IU/L, P = 0.023) and a significantly higher proportion of patients with mild inflammation(A1) on histological examination(70.6% vs 35.7%, P = 0.025). When multivariate analysis was performed to identify factors contributing to the response to UDCA monotherapy, only a serum ALT level of 200 IU/L or lower was found to be associated with a significant difference(P = 0.013).CONCLUSION To prevent adverse events related to corticosteroids, UDCA monotherapy for AIH needs to be considered in patients with a serum ALT level of 200 IU/L or lower. | Yuichi Torisu Masanori Nakano Keiko Takano Ryo Nakagawa Chisato Saeki Atsushi Hokari Tomohisa Ishikawa Masayuki Saruta Mikio Zeniya | 2017 | World Journal of Hepatology2017，9，1： | 3 |
| 4 | Effects of denosumab treatment in chronic liver disease patients with osteoporosis显示文摘BACKGROUND Effective treatment of osteoporosis is essential for improving morbidity and health-related quality of life in chronic liver disease(CLD)patients.Denosumab has been shown to increase bone mineral density(BMD)and decrease the risk of osteoporotic fracture in the general population.However,there are few reports evaluating the efficacy of denosumab in CLD patients.AIM To investigated the effects and safety of denosumab in CLD patients with osteoporosis.METHODS Sixty CLD patients with osteoporosis were subcutaneously administered denosumab once every 6 mo.The study period for evaluating efficacy and safety was 12 mo.Changes from baseline in BMD at the lumbar spine,femoral neck,and total hip were evaluated at 12 mo of denosumab treatment.Bone turnover and quality were assessed by measuring serum tartrate-resistant acid phosphatase-5b(bone resorption marker),serum total procollagen type I N-terminal propeptide(bone formation maker),and plasma pentosidine(bone quality marker).RESULTS Among the 405 CLD patients,138(34.1%)patients were diagnosed with osteoporosis;among these,78 patients met the exclusion criteria and thus 60 patients were finally included in the present study.The median percentage changes from baseline to 12 mo of denosumab treatment in BMD at the lumbar spine,femoral neck,and total hip were+4.44%,+3.71%,and+4.03%,respectively.Denosumab significantly improved BMD,regardless of sex,patient age,and presence of liver cirrhosis.Serum tartrate-resistant acid phosphatase-5b and procollagen type I N-terminal propeptide levels constantly and significantly declined after denosumab treatment(P<0.001).Plasma pentosidine levels were also significantly lower at 12 mo of treatment(P=0.010).No patients experienced fractures and moderate-to-severe adverse events,except for transient hypocalcemia.CONCLUSION Denosumab treatment was safe and increased BMD,suppressed bone turnover,and improved bone quality marker levels in CLD patients with osteoporosis,irrespective of differences in baseline characteristics. | Chisato Saeki Mitsuru Saito Tsunekazu Oikawa Masanori Nakano Yuichi Torisu Masayuki Saruta Akihito Tsubota | 2020 | World Journal of Gastroenterology2020，26，33： | 3 |
| 5 | Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma显示文摘As the incidence of hepatocellular carcinoma(HCC) caused by infection with the hepatotropic viruses hepatitis B and hepatitis C decreases, greater attention has become focused on HCC caused by nonalcoholic steatohepatitis(NASH), an advanced form of nonalcoholic fatty liver disease which has shown increasing prevalence in correspondence with the overall increase in metabolic syndrome over the recent decades. Several clinical population studies have shown a positive relationship between NASH and HCC, while also providing initial insights into the underlying mechanisms of HCC development from NASH. Research into the pathological progression of NASH to HCC has advanced by use of several beneficial rodent models. In this review, we summarize the established mouse models for preclinical research of NASH-associated HCC and discuss the underlying hepatic mechanisms of NASH-related tumorigenesis identified to date that could lead to new targets for treatment and prevention. | Kazuki Takakura Tsunekazu Oikawa Yoichi Tomita Yusuke Mizuno Masanori Nakano Chisato Saeki Yuichi Torisu Masayuki Saruta | 2018 | World Journal of Gastroenterology2018，24，18： | 2 |
| 6 | Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: a preliminary report显示文摘 | Torisu Y Ikeda K Kobayashi M | 2007 | Hepatol Res2007，37，7： | 1 |
| 7 | Glial progenitors in the brainstem give rise to malignant gliomas by platelet-derived growth factor stimulation显示文摘 | Masui K Suzuki SO Torisu R | 2010 | Glia2010，58，9： | 1 |
| 8 | Bone resorption bytartrate-resistant acid phosphatase-positive multinuclear cellsisolated from rheumatoid synovium显示文摘 | Fujikawa Y Shingu M Torisu T et a1 | 1996 | Br J Rheumatol1996，35，： | 1 |
| 9 | Genetic susceptibility to simple febrile seizures:interleukin-1beta promoter polymorphisms are associated with sporadic cases显示文摘 | Kira R Torisu H Takemoto M | 2005 | Neurosci Lett2005，384，3： | 1 |
| 10 | Five-to fifteen-year clinical re- suits and the radiographic evaluation of aeetabular changes after bipolar hip arthroplasty for femoral head osteonecrosis 显示文摘 | Tsumura H Torisu T Kaku N | 2005 | J Arthro- plasty2005，20，7： | 1 |
| 11 | Progressive stroke involving bilateral medial medulla expanding to spinal cord due to vertebral artery dissection显示文摘 | Hagiwara N Toyoda K Torisu R | 2007 | Cerebrovasc Dis2007，24，： | 1 |
| 12 | New approach to management of malignant ascites with a streptococcal preparation OK-432 : Improvement of host immunity and prolongation of survival 显示文摘 | Torisu M Katano M Kimura Y | 1983 | J Surg1983，93，3： | 1 |
| 13 | Suppressor of cytokine signaling 1 protects mice against concanavalin A-in- duced hepatitis by inhibiting apoptosis显示文摘 | TORISU T NAKAYA M WATANABE S l | 2008 | Hepatology2008，47，5： | 1 |
| 14 | Relationship between lymph node metastasis and E-cadherin expression in submueo- sal invasive gastric carcinomas with gastric-phenotype显示文摘 | Aoki R Yasuda M Torisu R | 2007 | J Med Invest2007，54，2： | 1 |
| 15 | Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan 显示文摘 | Torisu H Kira R Ishizaki Y | 2010 | Brain Dev2010，32，6： | 1 |
| 16 | Autophagy regulates endothelial cell processing, maturation and secretion of yon Willebrand factor 显示文摘 | Torisu T Torisu K Lee IH | 2013 | Nat Med2013，19，10： | 1 |
| 17 | Neutrophil-mediated tumor cell destruction in cancer ascites 显示文摘 | Katano M Torisu M | 1982 | Cancer1982，50，1： | 1 |
| 18 | Macrophage infiltration cor- relates with tumor stage and angiogenesis in human malig- nant mela noma:possible involvement of TNF alpha and IL-1 alpha显示文摘 | Torisu H Ono M Kiryu H | 2000 | Int J Cancer2000，85，2： | 1 |
| 19 | Isolated avulsion fracture of the tibial attachment of the posterior cruciate ligament显示文摘 | Torisu T | | 0，，01： | 1 |
| 20 | Avulsion fracture of the tibial attachment of the posterior cruciate ligament:indications and results of delayed repair显示文摘 | Torisu T | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员